Jan 8, 2015
Intezyne Technologies Announces Formation of its Clinical Advisor Board
July 10, 2014
Intezyne Technologies Expands Executive Leadership Team with Two Key Appointments
Jun 19, 2013
Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma
Intezyne’s IT-235 is a first-in-class targeted gallium-based small molecule administered as oral tablets once daily.
Intezyne, Inc. believes the IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy.